Skip to main content

Laura Jean Havrilesky, MD

Laura Havirlesky, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-0188
Email: havri001@mc.duke.edu

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer. The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women.

Education and Training

  • Residency, Obstetrics And Gynecology, Duke University, 1995 - 1999
  • M.D., Duke University, 1995

Research

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer.

The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women. 

Publications

Jewell, EL, Smrtka, M, Broadwater, G, Valea, F, Davis, DM, Nolte, KC, Valea, R, Myers, ER, and Havrilesky, LJ. "Preference-based utility scores for adverse events associated with the treatment of gynecologic cancers." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 23, no. 6 (January 1, 2013): 1158-1166.

Full Text

Bolac, CS, Wallace, AH, Broadwater, G, Havrilesky, LJ, and Habib, AS. "The impact of postoperative nausea and vomiting prophylaxis with dexamethasone on postoperative wound complications in patients undergoing laparotomy for endometrial cancer." Anesthesia and Analgesia 116, no. 5 (2013): 1041-1047.

Full Text

Lopez-Acevedo, M, Havrilesky, LJ, Broadwater, G, Kamal, AH, Abernethy, AP, Berchuck, A, Secord, AA, Tulsky, JA, Valea, F, and Lee, PS. "Timing of end-of-life care discussion with performance on end-of-life quality indicators in ovarian cancer." Gynecologic Oncology 130, no. 1 (2013): 156-161.

Full Text

Alvarez Secord, A, Bernardini, MQ, Broadwater, G, Grace, LA, Huang, Z, Baba, T, Kondoh, E, Sfakianos, G, Havrilesky, LJ, and Murphy, SK. "TP53 Status is Associated with Thrombospondin1 Expression In vitro. (Published online)" Front Oncol 3 (2013): 269-.

Full Text

Danesh, K, Durrett, R, Havrilesky, LJ, and Myers, E. "A branching process model of ovarian cancer." J Theor Biol 314 (December 7, 2012): 10-15.

Full Text

Giugale, LE, Di Santo, N, Smolkin, ME, Havrilesky, LJ, and Modesitt, SC. "Beyond mere obesity: effect of increasing obesity classifications on hysterectomy outcomes for uterine cancer/hyperplasia." Gynecol Oncol 127, no. 2 (November 2012): 326-331.

Full Text

Phippen, NT, Leath, CA, Chino, JP, Jewell, EL, Havrilesky, LJ, and Barnett, JC. "Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervix." Gynecol Oncol 127, no. 2 (November 2012): 267-272.

Full Text

Jr, MRJ, Alvarez, RD, Armstrong, DK, Burger, RA, Castells, M, Chen, L-M, Copeland, L, Crispens, MA, Gershenson, D, Gray, H, Hakam, A, Havrilesky, LJ, Johnston, C, Lele, S, Martin, L, Matulonis, UA, O'Malley, DM, Penson, RT, Remmenga, SW, Sabbatini, P, Santoso, JT, Schilder, RJ, Schink, J, Teng, N, Werner, TL, Hughes, M, and Dwyer, MA. "Ovarian Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines." JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK 10, no. 11 (November 2012): 1339-1349.

Full Text

Cantrell, LA, Havrilesky, L, Moore, DT, O'Malley, D, Liotta, M, Secord, AA, Nagel, CI, Cohn, DE, Fader, AN, Wallace, AH, Rose, P, and Gehrig, PA. "A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma." Gynecol Oncol 127, no. 1 (October 2012): 22-26.

Full Text

Secord, AA, Teoh, DK, Barry, WT, Yu, M, Broadwater, G, Havrilesky, LJ, Lee, PS, Berchuck, A, Lancaster, J, and Wenham, RM. "A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer." Clin Cancer Res 18, no. 19 (October 1, 2012): 5489-5498.

Full Text

Pages